CARMAT SAS has published the largest clinical study yet of its Aeson Total Artificial Heart, reporting that 72.7% of 55 patients with advanced biventricular heart failure were alive on Aeson support at 180 days or had undergone transplantation before that point without disabling stroke or major device failure requiring replacement, reoperation or urgent transplant. The result significantly exceeded the study’s prespecified 38% historical benchmark derived from earlier generations of total artificial hearts. EFICAS was conducted across ten French centers, presented at the European Society of Cardiology Congress 2026 and published in the European Heart Journal.
The patients were exceptionally sick before implantation, making the results clinically noteworthy. Median age was 56 years, 49% were classified in INTERMACS profiles 1 or 2, indicating critical cardiogenic shock or progressive decline, and 36% were already receiving VA-ECMO circulatory support when Aeson was implanted. These were not stable patients electing a futuristic device over a straightforward transplant; many had reached a point at which conventional support options were severely limited.
What exactly is a total artificial heart designed to replace?
Most mechanical circulatory-support devices assist only one chamber, particularly the left ventricle. A left ventricular assist device can be highly effective when the left side of the heart is failing but may not solve the problem when severe disease affects both ventricles or when structural abnormalities make conventional LVAD support unsuitable. A total artificial heart takes the much more radical approach of replacing the pumping function of both native ventricles.
Aeson is designed as a bioprosthetic, pulsatile and autoregulated total artificial heart. Instead of delivering one fixed output regardless of a patient’s changing physiological needs, the system is engineered to adjust blood flow in response to pressure and demand, attempting to reproduce aspects of natural cardiovascular regulation. The implanted heart remains connected to a portable external power system, allowing patients who recover sufficiently to leave hospital rather than remaining permanently attached to bedside equipment.
How many patients actually survived or reached transplantation successfully?
Forty of the 55 EFICAS participants met the composite primary endpoint, producing the 72.7% success rate. The endpoint counted patients who remained alive and supported by Aeson at 180 days or who received a donor-heart transplant before 180 days, provided they had avoided disabling stroke and major device malfunction requiring reoperation, replacement or urgent transplantation. The 95% confidence interval ranged from 57.1% to 85.1%, and the result was statistically superior to the 38% historical benchmark.
At 180 days, 96% of patients were free from disabling stroke and 76% had been discharged from hospital. Among surviving patients, 92% were classified in New York Heart Association functional class I or II, indicating no limitation or only mild limitation during ordinary physical activity. The study also reported a median 305-meter improvement in the six-minute walk test among patients evaluable at six months and a 40-point improvement in EQ-5D quality-of-life score.
Why are stroke and bleeding such important measures for an artificial heart?
Any mechanical device that continuously contacts blood creates a difficult engineering problem. Abnormal flow patterns and artificial surfaces can damage red blood cells, activate coagulation or create clots capable of traveling to the brain, while aggressive anticoagulation used to prevent thrombosis can itself increase bleeding. Earlier generations of mechanical circulatory-support technologies taught the industry that simply keeping blood moving is not enough; the device must do so without creating unacceptable neurological and hematological complications.
EFICAS therefore provides particularly useful information beyond overall survival. The study reported no hemolysis, 96% freedom from disabling stroke at 180 days and major bleeding events concentrated within the first 30 postoperative days. These findings are encouraging for a total artificial heart, although the patient population remains small and wider commercial use will be needed to understand uncommon device complications more precisely.
Why would a patient receive an artificial heart instead of a donor transplant?
The fundamental problem is organ scarcity. Heart transplantation can provide excellent outcomes for selected patients with end-stage heart failure, but the number of suitable donor hearts is far smaller than the number of people who could potentially benefit. Patients can deteriorate rapidly while waiting, and some become too unstable to survive until a donor organ is found.
Aeson is currently positioned primarily as a bridge to transplantation rather than a permanent replacement for every failing human heart. The device can theoretically stabilize circulation, reverse organ dysfunction caused by poor blood flow and give patients enough time to recover strength while remaining eligible for a donor heart. CARMAT reports that 122 Aeson implants have been performed worldwide to date, illustrating that the technology remains highly specialized rather than routine.
Could a total artificial heart eventually become permanent therapy?
That is one of the most consequential long-term possibilities, but EFICAS does not answer it. Bridge-to-transplant use has a defined endpoint: support the patient safely until a suitable donor organ becomes available. Destination therapy is much more demanding because the artificial heart would need to function reliably for years while minimizing infection, stroke, bleeding, mechanical wear and external-power burden.
The engineering trajectory points toward that ambition because every improvement in hemocompatibility, durability, battery technology and automatic flow regulation reduces dependence on transplantation. Yet long-term replacement also changes patient expectations. A device intended to function for years must support ordinary life rather than merely keep a critically ill patient alive while awaiting another operation.
What does the EFICAS study mean commercially for Aeson?
CARMAT says the results are important to securing reimbursement in France, which is essential if Aeson is to move from specialist clinical use into a more sustainable routine-care model. Regulatory authorization alone does not guarantee that hospitals can afford to implant an expensive total artificial heart, particularly when the procedure requires multidisciplinary cardiac surgery, intensive care, rehabilitation and long-term device support. EFICAS supplies the clinical-outcome evidence payers need when evaluating whether that total episode of care is justified.
The company has also gone through significant financial restructuring, with historical CARMAT SA entering judicial liquidation in January 2026 and CARMAT SAS continuing the operating activities. That corporate history makes reimbursement and sustainable adoption especially important because an advanced medical device can demonstrate remarkable engineering and still fail commercially if the manufacturer cannot fund production, service and clinical support at scale.
What should heart-failure specialists watch next?
The next important evidence will involve larger numbers and longer follow-up. Fifty-five patients constitute meaningful data for an extremely specialized total artificial heart, but they are not enough to fully define long-term reliability or rare adverse-event rates. Clinicians will also want to know whether outcomes remain as strong when implantation expands beyond the expert centers that participated in EFICAS.
The bigger question is whether artificial hearts can finally move beyond the historical image of experimental last-resort machines. EFICAS suggests Aeson can support some extremely sick patients long enough to leave hospital, regain walking capacity and reach transplantation without the rates of disabling stroke that plagued earlier eras. If reimbursement and longer-term reliability follow, the artificial heart may gradually become less science fiction and more recognizable infrastructure within advanced heart-failure care.
